Testing blood cancer DNA monitoring during CAR-T treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of follicular lymphoma, large B-cell lymphoma (including transformed follicular lymphoma and primary mediastinal B-cell lymphoma), or mantle cell lymphoma
- You are planning to start a CAR-T treatment that is already approved by the FDA for your situation (and your enrollment happens before CAR-T infusion)
- Your CAR-T product must meet the manufacturer’s specifications
- At the time CAR-T is being considered, imaging shows you have measurable disease on PET scan
- You have stored or available biopsy samples (from diagnosis or relapse) so researchers can read your cancer’s DNA “fingerprint” for monitoring
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.